GlassScriptPhysician profile
Cecil F Bennett
NPI 1982773610
$2,181.79
in general payments reported to CMS, 2019-2025
34 companies · $336 in 2025
The $336 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23.14 · 2020: $67.85 · 2021: $387 · 2022: $355 · 2023: $451 · 2024: $562 · 2025: $336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,321 · Entertainment: $28.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,320.97 |
| Entertainment | $28.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $367.13 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $265.81 | 2021-2024 | Mounjaro, Jardiance, Trulicity |
| Bayer Healthcare Pharmaceuticals INC. | $223.70 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $157.82 | 2022-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.61 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Pfizer INC. | $79.28 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $75.31 | 2021-2024 | Xifaxan |
| Eisai INC. | $73.20 | 2021 | |
| Abbvie INC. | $67.38 | 2023-2024 | Qulipta |
| Mylan Specialty L.P. | $61.84 | 2023-2024 | Yupelri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $58.73 | 2024 | Caplyta |
| Amgen INC. | $58.57 | 2020-2024 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $57.78 | 2022-2025 | Spravato |
| Medtronic, INC. | $51.30 | 2021-2024 | Intellis Adaptivestim |
| Exact Sciences Corporation | $49.76 | 2024-2025 | Cologuard Collection Kit |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $35.72 | 2023 | Veozah |
| Glaxosmithkline, LLC. | $34.90 | 2021-2024 | Shingrix, Arexvy |
| Azurity Pharmaceuticals, INC. | $33.79 | 2025 | Azmiro |
| Gilead Sciences, INC. | $30.52 | 2021-2024 | |
| Optos, INC. | $28.38 | 2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Viiv Healthcare Company | $21.87 | 2024 | Apretude |
| Actelion Pharmaceuticals US, INC. | $20.01 | 2025 | Opsumit, Uptravi |
| Astrazeneca Pharmaceuticals LP | $19.87 | 2022 | |
| Idorsia Pharmaceuticals US INC | $19.61 | 2023 | Quviviq |
| Allergan, INC. | $19.29 | 2021 | |
| Paratek Pharmaceuticals, INC. | $18.92 | 2024 | Nuzyra |
| Novartis Pharmaceuticals Corporation | $18.62 | 2021 | |
| Xeris Pharmaceuticals, INC. | $17.82 | 2025 | Gvoke Hypopen |
| Globus Medical, INC. | $15.82 | 2025 | Vyrsa V1 |
| Sumitomo Pharma America, INC. | $15.54 | 2025 | Gemtesa |
| Linus Health, INC. | $15.09 | 2023 | |
| Esperion Therapeutics, INC. | $13.40 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.40 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cecil Bennett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.